In fact, GLP-1 receptor agonists have a more favourable profile in terms of glycaemic control and body weight reduction, whereas in terms of hard clinical endpoints SGLT-2 inhibitors predominantly reduce hospitalisations for worsening HF and ameliorate progression of CKD, while GLP-1 receptor agonists may have more pronounced effects against myocardial infarction and ischaemic stroke [4]. The gene discussed is SLC5A2; the disease is hydrops fetalis.